| 查看: 1790 | 回复: 101 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
本人考085602 化学工程 专硕
已经有23人回复
-
求调剂院校信息
已经有4人回复
-
085600材料与化工306
已经有4人回复
-
286求调剂
已经有10人回复
-
328求调剂，英语六级551，有科研经历
已经有9人回复
-
一志愿北京化工大学070300 学硕336求调剂
已经有4人回复
-
286分人工智能专业请求调剂愿意跨考！
已经有8人回复
-
资源与环境 调剂申请(333分)
已经有5人回复
-
280求调剂
已经有12人回复
-
269专硕求调剂
已经有5人回复
» 抢金币啦！回帖就可以得到:
-
春天就该逛吃逛吃
+1/81
-
散金币，求好运，祝面上顺利！
+2/66
-
江苏科技大学能源材料化学课题组郭兴梅教授招收博士研究生1-2名
+1/46
-
欢迎交流咨询
+1/42
-
上海交通大学沈道智副教授招收2026年联培博士/硕士研究生（微纳器件与制造方向）
+1/33
-
西安某大学能源化工新材料研发项目组接收2026级调剂研究生-计算机类
+1/32
-
南京理工大学优青团队招聘副教授、博士后、博士、硕士生（化学、催化方向）
+1/30
-
武汉工程大学资源生物技术课题组生物/环境/化工/矿物专业硕士、博士研究生招生及调剂
+2/30
-
浙江中医药大学副校长团队招聘药学/生物信息学等方向高校教师7名，报名通道已开启
+1/15
-
湖南大学微生物结构与功能实验室2026年计划招收博士研究生
+1/15
-
中国中医科学院中医药健康产业研究所（江西中医药健康产业研究院）2026年高层次人才等
+1/9
-
多伦多大学 & Synetic Labs 招博士后/研究员
+1/8
-
南开大学陈树琪教授研究团队招收2026级超构材料方向博士研究生
+1/8
-
211/双一流---石河子大学---有机化学方向招调剂生
+1/6
-
宁波东方理工大学余鹏课题组2026年上海交大联培博士生、博士后、科研助理招聘
+1/6
-
招收化工与材料学科点研究生
+1/3
-
天津大学理学院分离分析及功能材料研究组
+1/3
-
深圳大学蔡兴科课题组博士后及研究助理招聘
+1/1
-
西安交通大学生命学院智能化诊疗装备研究中心2026年博士生招生
+1/1
-
“机械、材料”招生
+1/1
86楼2015-11-20 16:22:10
简单回复
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
